The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pyrimidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a...

The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts

The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pynmidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a ...

The present invention relates to a composition for inhibiting after-cataract comprising hydrophilic sulfasalazine, a high content of hyaluronic acid, and a carrier comprising an acqueous solution, and a method for preparing the composition for inhibiting after-cataract by adding a hyaluronic acid powder to sulfasalazine that is hydrophillized, and mixing same according to specific reaction conditions.

The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pynmidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a ...

The invention relates to methods of selecting a subject and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug) such as gold salts; hydroxychloroquine; an antifolate such as methotrexate; a pynmidine synthesis inhibitor such as leflunomide; or a sulfa drug such as sulfasalazine. For example the DMARD can be methotrexate administered at a dose of mg/week or less; leflunomide administered at a ...